This report presents the results of the first external quality assurance (EQA) scheme for B. pertussis antimicrobial susceptibility testing by ECDC as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) consortium.
This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
This report presents the results of the ECDC European Reference Laboratory Network for Pertussis (ERLNPert-Net) external quality assessment (EQA) scheme for Bordetella pertussis PCR, funded by ECDC on behalf of ERLNPert-Net and conducted from April to September 2020. The EQA was organised by the National Institute for Biological Standards and Control (NIBSC), based in Potter’s Bar, United Kingdom (UK).
External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues and deployment of resources and training where necessary.
External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues and deployment of resources and training where necessary.
External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues, and deployment of resources and training where necessary.
A pilot project was carried out to investigate the feasibility of HIVDR surveillance in EU/EEA countries and to make recommendations for the design and implementation of a potential future HIVDR surveillance system at the European level.
The overall aim of Euro-GASP is to strengthen the surveillance of gonococcal antimicrobial susceptibility in EU/EEA Member States in order to provide quality-assured data to inform gonorrhoea treatment guidelines. This report presents the results from the 2017 gonococcal antimicrobial susceptibility sentinel surveillance.
This report presents the results of the second European Pertussis Laboratory Surveillance Network (EUPert-LabNet) EQA scheme for Bordetella pertussis PCR funded by ECDC on behalf of EUPert-LabNet. The EQA study was conducted between February and March 2018.
The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.